Pounce on This Biotech Favorite If it Falls Back Into Buying Range

CELG broke from a rectangle consolidation, forming a steep bull channel

   
Pounce on This Biotech Favorite If it Falls Back Into Buying Range

Celgene Corp. (NASDAQ:CELG) — This company develops small molecule drugs for the treatment of blood-borne and solid-tumor cancers and inflammatory diseases. The stock has been on the Trade of the Day buy list for over a year, and in January, S&P said it had “the brightest growth prospects among large-cap biotech companies.” 

On Jan. 9, I wrote, “Management provided encouraging guidance by adjusting earnings expectations for 2013 to $5.50-$5.60, up from a Zacks estimate of $4.91. The company’s oncology drug, Abraxane, is expected to be a blockbuster with sales estimates of $1 billion to $1.5 billion in 2015. And, according to management, it has other potentially high revenue drugs in its pipeline.”

Since then, S&P has boosted its target to $125. Analysts’ targets now range from $115 to $137.

In early January, CELG broke from a classic cup-and-handle on high volume followed by a breakaway gap. The stock then consolidated in a rectangle, and in late February, broke from it, forming a steep bull channel. From a technical analysis standpoint, it just doesn’t get better than this. The stock consolidates, pauses to gain new strength, and then breaks out again. 

The trading target remains $118 to $120, but the stock could go higher since short sellers have increased their positions by 48% to 5.53 million shares and now represent more than 1% of the float. Continue to hold CELG for our target of $125 and buy on pullbacks under $108.

03 18 12 celg 300x199 Pounce on This Biotech Favorite If it Falls Back Into Buying Range
Click to Enlarge

chart key 300x84 Pounce on This Biotech Favorite If it Falls Back Into Buying Range


Article printed from InvestorPlace Media, http://investorplace.com/2013/03/trade-of-the-day-celgene-corp-nasdaq-celg-6/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.